Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Monday . The stock had previously closed at $15.06, but opened at $15.91. Ascentage Pharma Group International shares last traded at $15.98, with a volume of 6,704 shares traded.

Wall Street Analyst Weigh In

AAPG has been the subject of several recent analyst reports. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Finally, B. Riley Financial assumed coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, Ascentage Pharma Group International presently has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Up 0.1%

The company has a fifty day moving average price of $17.63 and a 200-day moving average price of $20.05. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.